KURA News and Press, Kura Oncology Inc. From 04/03/19

Kura Oncology ( KURA +1.3% ) is up on below-average volume following the presentation of new data supporting the mechanism of action of lead drug tipifarnib at AACR in Atlanta. More news on: Kura Oncology, Inc., Healthcare stocks news, Stocks on the move, Read more ...

– Tipifarnib is a farnesyl transferase inhibitor that downregulates CXCL12 – – Gene expression of the exclusively farnesylated RHOE and PRICKLE2 proteins associated with CXCL12 expression – – Pre-treatment tumor CXCL12 expression identified as a potent...

Kura Oncology, Inc. (KURA) Q4 2018 Results Earnings Conference Call March 05, 2019, 04:30 PM ET Company Participants Pete De Spain - VP, IR and Corporate Communications Troy Wilson - President and CEO Marc Grasso - CFO and Chief Business Officer Antonio Gualberto - Head, Develo...

Kura Oncology (NASDAQ: KURA ): Q4 GAAP EPS of -$0.42 in-line. More news on: Kura Oncology, Earnings news and commentary, Healthcare stocks news, Read more ...

– Registration-directed trial of tipifarnib in HRAS mutant HNSCC underway – – Data from three ongoing Phase 2 trials of tipifarnib anticipated this year – – Third drug candidate menin-MLL inhibitor KO-539 poised to enter clinic next quarter – ...

– KO-539 is a potent, selective small molecule inhibitor of the menin-MLL interaction – – Robust anti-tumor activity observed in mixed lineage leukemias rearranged and oncogenic driver mutations in genes such as NPM1 – – Phase 1 clinical trial in rela...

SAN DIEGO, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report fourth quarter and full year 2018 financial results after the close...

SAN DIEGO, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to p...

There are no facts, only interpretations. " - Friedrich Nietzsche Today, we look at a ' Tier 4 ' biotech concern. The firm has an intriguing pipeline, and there was some heavy buying in the stock in December by a beneficial owner. Company Overview: Founded in 2014, Kura Oncology ...

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signi...